# US 8,277,839 B2 · Oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,839 B2
- Document ID: US8277839B2
- Status: Granted
- Kind: B2
- Application number: 12/307,605
- Filed: 2007-07-05
- Published: 2009-12-31
- Granted: 2012-10-02
- Earliest claimed: 2006-07-06
- Assignees: Ares Trading S.A.
- Inventors: Santa Fabiano; Mario Maio
- Web page: https://patentgrep.com/patent/US8277839B2

## CPC

- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated in a hard gelatin capsules and can be used for the preparation of a medicament for the treatment of cancer in particular AML.

## Claims

### Claim 1

An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition said liquid composition comprising between 5% and 15% of
an anilinopyrimidine of Formula (I) as active ingredient
between 65% and 85% of a polyethylene glycol with an average molecular weight of between 3500 and 4500, and between 10% and 20% of a polyethylene glycol with an average molecular weight of between 570 to 630.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said pharmaceutically acceptable excipient is in a liquid form.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein it comprises 11% of the anilinopyrimidine of Formula (I), 79% of the polyethylene glycol with an average molecular weight of between 3500 and 4500, and 10% of the polyethylene glycol with an average molecular weight of between 570 to 630.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a glyceryl ester of capric acid.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein it comprises an equimolar mixture of the glyceryl ester of capric acid and a polyethylene glycol with an average molecular weight comprised between 570 and 630.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the capsule dosage form is a liquid-filled capsule.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the liquid fill composition is a thermoplastic suspension.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the thermoplastic suspension becomes solid after filling.

### Claim 9 (depends on 6)

The pharmaceutical composition according claim 6, wherein said capsule dosage form is a hard capsule.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein said capsule dosage form is a hard gelatine capsule size 00.

### Claim 11 (depends on 1)

A method of treating a cancer responsive to inhibition of IKK comprising administering a therapeutically effective amount of an oral pharmaceutical composition of claim 1 to an individual in need thereof.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the cancer is acute myeloid leukemia.

### Claim 13 (depends on 5)

The pharmaceutical composition of claim 5 wherein the glyceryl ester of capric acid is glyceryl monocaprate.
